The year's most popular stories

Share this article:
The year's most popular stories
The year's most popular stories

There are lots of ways to write the kind of story that ends up on a list like this. You could take a deep dive sharing exclusive projections for industry marketing spend. You can seriously examine the aggressive pricing for oncology drugs in the US. Or you can pen a commentary about Angelina Jolie's views on holistic treatment.

MM&M's year-end list also captures approval and pipeline analysis (Eliquis, Sovaldi, Lemtrada), insights into what doctors need—as opposed to what pharma thinks they want—and a look at medical advertising's best DTC ads ever. Here are the 10 that sparked heaviest reader interest in 2013:

1. Angelina Jolie's flawed message

2. Healthcare Marketers Trend Report: The Big Shift

3. Will Kadcyla suffer the same fate as Zaltrap?

4. Year-end approval clears Eliquis for launch

5. Docs to pharma marketers: you're not getting it

6. Merck buys controlling stake in Physicians Interactive

7. Lemtrada's future in doubt after reviewers flag safety issues

8. MM&M's Best DTC Ads Ever

9. Is the current agency model a joke?

10. The Pipeline Report 2014: Class Seekers

Share this article:
close

Next Article in News

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.